The anti-inflammatory effect of CM in animals with NAFLD coincides with the action of the PPAR-α agonists fibrates [55] and the PPAR-γ agonists, e.g., TZDs and troglitazone, that inhibit TNF-α expression and action in adipocytes and inhibit TNF-α-mediated IR [56]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.